Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Primary Malignancies News

Page 2 - Primary Malignancies News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Primary Malignancies. Real-time updates on events, politics, business and more.

New IMBRUVICA® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia

June 10, 2022
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating...
Comunidad Autonoma De Cataluna Sant Pau Carol Moreno Christie Corbett None Of The Janssen Pharmaceutical Companies Abbvie Company
Source: prnewswire.com

Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma

June 3, 2022
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the Phase 3 SHINE study (Abstract #7502), which...
United States Craig Tendler Michaell Wang Christie Corbett Global Medical Affairs Abbvie Company
Source: prnewswire.com

Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma

June 3, 2022
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the Phase 3 SHINE study (Abstract #7502), which...
United States Craig Tendler Michaell Wang Christie Corbett Global Medical Affairs Abbvie Company
Source: prnewswire.com

Johnson & Johnson : New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia

December 11, 2021
Updated results from the MRD cohort of the Phase 2 CAPTIVATE study also highlight potential for treatment-free remissions with IMBRUVICA® plus venetoclax in an oral presentation at ASH... | December 11, 2021
United States Craig Tendler Obinutuzumab Clb Bernadette King Jessica Moore Christie Corbett
Source: marketscreener.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs

June 1, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral...
United States Serge Messerlian Teclistamab Bcmax Peter Lebowitz Janssen Biotech Inc American Society Of Clinical Oncology
Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science